SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is experiencing significant volatility and intense community debate as investors navigate a disconnect between its strong growth narrative and a persistent stock price slide near 52-week lows. While bulls point to robust product demand, the Alani Nu acquisition, and a potential post-earnings recovery, many are frustrated by the stock's failure to participate in broader market rallies, leading to heightened speculation about institutional manipulation and upcoming earnings catalysts.

Applied Digital Corporation

Applied Digital is trending as investors bet on its massive backlog of AI data center contracts and infrastructure capacity, leading to strong bullish momentum and active discussion regarding a potential short squeeze. The community is focused on the stock's ability to maintain its upward trajectory toward new highs as it continues to execute on its large-scale AI hyperscaler partnerships.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors digest a surprise revenue beat and significant cost reductions following the latest earnings call, while community discourse remains intensely focused on the potential of the Matrix-M adjuvant and activist pressure for management changes. Sentiment remains polarized between those betting on long-term partnership success and shareholders frustrated by stalled pipeline execution and the ongoing proxy battle.

Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. It is involved in the development of mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. The company was founded in 1984 and is headquartered in Cambridge, MA.

Ernexa Therapeutics Inc.

Ernexa Therapeutics Inc

Ernexa Therapeutics is trending after announcing a strategic manufacturing partnership with Cellipont Bioservices to advance its ERNA-101 ovarian cancer therapy toward clinical trials. While some investors are excited by the potential for a short squeeze given the stock's low float and high volume, others remain skeptical, citing concerns over historical dilution and the speculative nature of early-stage biotech.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is rallying as investors react to the company's $625 million acquisition of Mirantis, a move viewed as a strategic pivot to integrate cloud software capabilities and strengthen its competitive position in the AI infrastructure sector. Community discussion is currently fixated on potential upcoming hyperscaler contract announcements, with many highlighting the stock as a key play for exposure to the power-constrained AI buildout.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending following an official determination from NOAA that its deep-seabed mining application is in full compliance, a key milestone that clarifies the regulatory path toward commercial operations. Community members are actively debating the significance of this news for long-term permitting and discussing whether the stock is positioned for a sustained rally despite recent volatility.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is seeing intense community speculation as traders position for upcoming earnings, with many focusing on the potential for a short squeeze or a major move based on management's turnaround strategy. Discussions are heavily divided between bullish sentiment regarding the company's housing technology, institutional accumulation, and AI initiatives, versus skepticism about the firm's long-term housing market performance and profitability.

Riot Platforms, Inc. is a bitcoin mining company, which engages in the provision of special cryptocurrency mining computers. It invests in Verady, Coinsquare, and Tess. It operates through the Bitcoin Mining and Engineering segments. The Bitcoin Mining segment focuses on maximizing ability to successfully mine Bitcoin by growing hash rate. The Engineering segment designs and manufactures power distribution equipment and custom engineered electrical products that provides them the ability to vertically integrate many of the critical electrical components and engineering service. The company was founded on July 24, 2000 and is headquartered in Castle Rock, CO.

Riot Platforms Inc

Riot Platforms is surging as investors pivot toward its expanding role in AI infrastructure and data center hosting, underscored by an ongoing partnership with AMD and strategic power-focused site development. Community sentiment remains highly energized around the stock's potential as a multi-gigawatt compute leader, with traders actively monitoring technical breakouts and potential short-squeeze activity.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is attracting significant community attention as investors pivot toward its rapidly expanding Wegovy oral pipeline, viewing recent pricing pressures as an overreaction to a structurally robust growth story. The sentiment is fueled by positive script volume data and strategic expansion, with bulls betting that the stock is currently disconnected from its long-term market dominance and defensive value.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is seeing significant volatility following a record-breaking earnings report that highlighted strong revenue growth, improved margins, and robust bookings. Community members are actively debating the sustainability of the stock's recent momentum, with some focusing on its long-term potential as a rugged edge-computing and defense infrastructure play, while others remain cautious of short-term pullbacks and selling pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>CEO Ng George K bought 2,136 shares of the company for a total purchase value of about $5415, the filing shows.</li><li>Overall, all the insiders cumulatively bought 16,175 shares of the company for a total purchase value of about $40,000.&nbsp;</li><li>Processa develops drugs for life-threatening and life-compromising chronic diseases.</li></ul>Shares of Processa Pharmaceuticals, Inc. (PCSA) closed up 6% and edged up 10% after hours on Thursday after several insiders at the company, including the CEO, made share purchases.According to filings made with the Securities and Exchange Commission, several insiders including Director Baluch Khoso, Chief Development Officer Bigora Sian, Chief Administrative Officer Guy Wendy, Chief Business Strategy Officer Lin Patrick, Chief Executive Officer Ng George K, Director Pannu Geraldine, Chief Financial Officer Skibsted Russell, President of Research &amp; Development Young David all bought shares of the company at a price of about $2.535 on the last day of March.CEO Ng George K bought 2,136 shares of the company for a total purchase value of about $5415, the filing shows. Overall, all the insiders cumulatively bought 16,175 shares of the company for a total purchase value of about $40,000.<h2 class="st-heading-2">About Processa</h2>Processa develops drugs for life-threatening and life-compromising chronic diseases. Its pipeline includes NGC-Cap and NGC-Iri for the treatment of certain cancers, PCS12852 for gastroparesis and constipation disorders and PCS499 for primary glomerular diseases. While the company has completed early-to-mid stage studies for PCS12852 and PCS499, mid-stage trials are in process for NGC-Cap. NGC-Iri, meanwhile, is still in preclinical stages.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around PCSA stock rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.“Nice to see the little token insider purchases apparent "ploy" working just as designed. Predictable, like death and taxes,” a Stocktwits user wrote.<stembedurl>https://www.stocktwits.com/Jwa68/message/649316897</stembedurl>Another voiced optimism for the stock rallying up to $20.<stembedurl>https://www.stocktwits.com/Shallu/message/649328642</stembedurl><a href="https://stocktwits.com/symbol/PCSA">PCSA stock</a> has lost nearly 63% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lpcn-stock-crashes-heres-why/cZ7x6c9RI88">LPCN Stock Crashes 78%— Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

PCSA Stock Rallies 10% After Hours— Here’s Why

According to filings made with the Securities and Exchange Commission, several insiders bought shares of the company at a price of about $2.535 on the last day of March. 

Equity

According to filings made with the Securities and Exchange Commission, several insiders bought shares of the company at a price of about $2.535 on the last day of March. 


PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study

Processa Pharmaceuticals stock jumps 122% after a phase II update shows NGC-Cap delivers higher active metabolite exposure with comparable safety in breast cancer.

Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?

Processa Pharmaceuticals' stock jumps after Phase 2 data show higher capecitabine exposure without added toxicity in metastatic breast cancer patients.read more...

<ul class="summary-bullets"><li>Hut 8 shares were up more than 11% in Wednesday’s midday trade after the company announced that it is building an AI data center for Anthropic.</li><li>Processa Pharmaceuticals' shares were up nearly 95% after early Phase 2 data showed that its NGC-Cap therapy boosts capecitabine exposure without added side effects compared with standard treatment.</li><li>Recursion Pharmaceuticals shares jumped over 16% by midday Wednesday after Morgan Stanley upgraded the stock to ‘Overweight’ and raised its price target to $11, citing strong efficacy for its drug REC-4881.</li></ul>U.S. equities were in the red in Wednesday’s midday trade as investors exercised caution amid a broader decline in artificial intelligence stocks, with Oracle and Broadcom shares declining by nearly 5% each.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was down 0.68% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq 100 index, declined 1.28%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, fell 0.2%.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Wednesday’s midday trade:</h2><a href="https://stocktwits.com/symbol/ORCL">Oracle Corp. (ORCL)</a>Oracle shares were down over 5% in Wednesday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oracle-s-ai-expansion-hits-snag-as-key-investor-pulls-back-report/cLeO1HSREqa">faced</a> a setback in its AI data center expansion efforts after Blue Owl Capital reportedly withdrew from a $10 billion investment in the company’s new facility in Saline Township, Michigan.<a href="https://stocktwits.com/symbol/ORCL">ORCL stock</a> is up 8% year-to-date.<a href="https://stocktwits.com/symbol/HUT">Hut 8 Corp. (HUT)</a>Hut 8 shares were up more than 11% in Wednesday’s midday trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hut-shares-soar-over-24-percet-today-whats-the-deal-involving-google-and-anthropic/cLeO1aZREqJ">announced</a> that it is building an AI data center for Anthropic, and that it had signed a 15-year, $7 billion lease with Fluidstack. The company added that the lease would be worth up to $17.7 billion if all renewal options are exercised.<a href="https://stocktwits.com/symbol/HUT">HUT stock</a> is up 100% year-to-date.<a href="https://stocktwits.com/symbol/PCSA">Processa Pharmaceuticals Inc. (PCSA)</a>Processa Pharmaceuticals share price nearly doubled, hovering at gains of 95% in Wednesday’s midday trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-processa-pharmaceuticals-stock-surge-160-today/cLeOVJlREqV">stated</a> that its early Phase 2 trial data showed that its NGC-Cap therapy significantly increases exposure to capecitabine cancer-killing drug metabolites without increasing the severity of side effects compared to standard monotherapy capecitabine therapy.<a href="https://stocktwits.com/symbol/PCSA">PCSA stock</a> is down 73% year-to-date.<a href="https://stocktwits.com/symbol/RXRX">Recursion Pharmaceuticals Inc. (RXRX)</a>Recursion Pharmaceuticals shares were up over 16% in Wednesday’s midday session after Morgan Stanley upgraded the stock to ‘Overweight’ from ‘Neutral’, according to TheFly. The firm also hiked its price target for the RXRX stock to $11 from $10, citing “strong and durable” efficacy in familial adenomatous polyposis from the company's small-molecule drug, REC-4881.<a href="https://stocktwits.com/symbol/RXRX">RXRX stock</a> is down 28% year-to-date.<a href="https://stocktwits.com/symbol/UDMY">Udemy Inc. (UDMY)</a>Udemy shares were up more than 22% in Wednesday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cour-udmy-stock-premarket-coursera-udemy-announce-merger/cLeOKUtREq4">announced</a> a merger with Coursera Inc. (COUR), with an implied equity value of the combined entity of approximately $2.5 billion.<a href="https://stocktwits.com/symbol/UDMY">UDMY stock</a> is down 20% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/waller-fed-chair-odds-surge-after-dovish-comments/cLeOjlBREqg">Waller's Odds For Fed Chair Nomination Surge After The Fed Governor's Dovish Comments On Rate Cuts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks Making The Biggest Moves Today

Oracle shares were down over 5% in Wednesday’s midday session after Blue Owl Capital reportedly withdrew from a $10 billion investment in the company’s new facility in Saline Township, Michigan.

<ul class="summary-bullets"><li>Processa plans to complete enrollment for the formal 20-patient interim analysis by the end of the first quarter of 2026.</li><li>The company’s stock also began trading on a 1-for-25 reverse stock split basis on Wednesday.</li><li>Trading in PCSA shares was halted multiple times today, according to Nasdaq data.</li></ul>Processa Pharmaceuticals Inc. (PCSA) surged over 160% on Wednesday, after the company announced that early Phase 2 data showed that its Next Generation Cancer (NGC) therapy delivered higher levels of cancer-fighting metabolites in patients with advanced or metastatic breast cancer.The company’s stock also began trading on a 1-for-25 reverse stock split basis on Wednesday. Trading in <a href="https://stocktwits.com/symbol/PCSA">PCSA shares</a> was halted multiple times on Wednesday, according to Nasdaq data.<h2 class="st-heading-2">Phase 2 Study Results&nbsp;</h2>Preliminary data from the first 16 of 19 enrolled patients indicated that NGC-Cap significantly increases exposure to capecitabine’s cancer-killing metabolites compared with standard capecitabine monotherapy without increasing the severity of side effects seen with standard treatment. The company believes the balance could improve outcomes for patients with advanced breast cancer.Nineteen patients were randomized to receive either NGC-Cap (150 mg twice daily) or standard Mono-Cap (1,000 mg/m² twice daily). Early safety data from the first 16 patients show higher exposure to cancer-killing metabolites in the NGC-Cap group.While more patients in the NGC-Cap group experienced side effects related to these metabolites, the severity was similar to that in the Mono-Cap group.&nbsp;Processa plans to complete enrollment for the formal 20-patient interim analysis, which will include both safety and efficacy data, by the end of the first quarter of 2026. The company expects to report the interim analysis in early 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’, amid ‘extremely high’ message volumes. PCSA was the top trending ticker on Stocktwits.<figure class="image"><img style="aspect-ratio:922/93;" src="https://news.stocktwits-cdn.com/PCSA_png_df422e4216.webp" alt="PCSA.png" width="922" height="93"><figcaption>PCSA's Sentiment Meter and Message Volumes at 11:30 a.m. ET on Dec. 17, 2025 | Source: Stocktwits</figcaption></figure>One Stocktwits user expects further upside to the stock.<stembedurl>https://stocktwits.com/AJWW316/message/639440673</stembedurl>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/uwm-holdings-to-acquire-two-harbors-investment-in-1-3-b-deal/cLeOjLYREqf">UWM Holdings To Acquire Two Harbors Investment In $1.3B Deal - How Much Of The Combined Company Will UWM Shareholders Own?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Why Did Processa Pharmaceuticals Stock Surge 160% Today?

The company announced that early Phase 2 data showed that its NGC therapy increased cancer-fighting metabolites in patients with advanced breast cancer.

Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. Its main product candidate is PCS499, which is intended for the treatment of Necrobiosis Lipoidica. The company was founded by David Young, Patrick Lin, Sian E. Bigora, Wendy Guy, and Chang Rung Chen on March 29, 2011 and is headquartered in Vero Beach, FL.

Processa Pharmaceuticals Inc

Still early innings

Overdone

Consolidation due before next leg up

Memory stocks have surged over the past year - is the run overdone or still early innings?

PCSA
Processa Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Poll

Latest PCSA News

PCSAProcessa Pharmaceuticals Inc